NASDAQ · STOCK
Edwards Lifesciences
$92.17
52W $72.30 – $96.29
64/100
$52.59B
48.5
0.83
Price History (6M)
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Executive Summary
4 analysts weighed in with 100% agreement on a bullish lean. Growth Analyst: Quarter-over-quarter growth rate is ACCELERATING, not just positive. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily trend: uptrend.
- Weekly trend: uptrend.
- Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Risk/reward is unfavorable: 7.2% downside vs 2.9% upside.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
64/100
Agreement
71%
Analysts
7
Conviction
Contested
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
bullish
63
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
54.5
Neutral
MACD Histogram
0.073
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$85.58
Resistance
$94.87
Bollinger %B
0.68
Inside Bands
Price vs Moving Averages
EMA 9
$92.26
Below
EMA 21
$90.39
Above
EMA 50
$87.47
Above
EMA 200
$83.08
Above
Fundamental Analysis
Valuation
25
Growth
57
Profitability
80
Financial Health
100
Valuation
P/E Ratio
48.5×
P/B Ratio
4.79×
PEG Ratio
—
Dividend Yield
—
52W High
$96.29
52W Low
$72.30
Quality & Growth
ROE
1059.0%
ROA
815.0%
Gross Margin
7787.0%
Operating Margin
1708.0%
Revenue Growth YoY
+1381.0%
Debt / Equity
0.06
AI Fundamental Assessment
P/E ratio of 48.5 (rich relative to a 15-40x range); Price-to-book of 4.8x; Revenue growth (YoY) of 13.8%; EPS growth (YoY) of -73.2%; Return on equity of 10.6%; Return on assets of 8.2%; Net margin of 17.4%; Gross margin of 77.9%; Current ratio of 3.72 (healthy short-term liquidity); Debt-to-equity of 0.06; Most recent quarter beat estimates by 4.2%; EPS growth accelerating (-13.4% -> +34.5% QoQ); Analyst estimates rising over recent quarters
Key Risks
- Risk/reward is unfavorable: 7.2% downside vs 2.9% upside.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full EW Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile